Results 11 to 20 of about 46,150 (319)
Pulmonary Circulation, 2021 Spironolactone, a common diuretic used in the treatment of pulmonary arterial hypertension (PAH), improves cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on endothelin type‐B receptor function within pulmonary ...
Zeenat Safdar, Eunah Cho
doaj +1 more source
Frontiers in Medicine, 2021 Purpose: On the basis that spironolactone is involved in ACE2 expression and TMPRSS2 activity, previous studies have suggested that spironolactone may influence the infectivity of COVID-19.
Dongsub Jeon, Minkook Son, Jonggi Choi
doaj +1 more source
Frontiers in Pharmacology, 2023 Renal sodium retention is an essential indicator that is used for the prognosis of cirrhosis with ascites that requires diuretic treatment to restore sodium homeostasis.
Tun-Pin Hsueh +5 more
doaj +1 more source
Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver [PDF]
, 1987 Spironolactone and potassium canrenoate are diuretics that are used widely for management of cirrhotic ascites. The administration of spironolactone frequently leads to feminization, which has been noted less frequently with the use of potassium ...
Alfredo Di Leo +46 more
core +1 more source
Archives of Medical Science, 2019 Introduction The aim of the current study was to evaluate the association of spironolactone and arterial stiffness and composite cardiovascular disease (CVD, including coronary heart disease, congestive heart failure and ischemic stroke) in hypertensive ...
Fanfang Zeng +5 more
doaj +1 more source
Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model [PDF]
Diabetes & Metabolism Journal, 2011 BackgroundWhile there is an evidence that the anti-inflammatory properties of spironolactone can attenuate proteinuria in type 2 diabetes, its effects on vascular endothelial growth factor (VEGF) expression in diabetic nephropathy have not been clearly ...
Mi Young Lee +10 more
doaj +1 more source
Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study [PDF]
, 2017 Spironolactone improves outcome in dogs with advanced myxomatous mitral valve disease (MMVD). Its efficacy in preclinical MMVD is unknown. The hypothesis was the administration of spironolactone to dogs with compensated MMVD demonstrating risk factors ...
Boswood, A +4 more
core +3 more sources
Clinical and Translational Science, 2022 This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK+) in patients with heart failure (HF) with preserved or mildly reduced ...
Iain B. Squire +11 more
doaj +1 more source
Efficacy and Safety of Spironolactone in the Treatment of Resistant Hypertension：a Meta-analysis [PDF]
Zhongguo quanke yixue, 2022 BackgroundAs a special type of hypertension, resistant hypertension has complex etiology, is difficult to treat, and more likely to lead to target organ damage.
ZHANG Ping, ZOU Jing, GAO Cunzhou, WU Aiping, LI Rongshan
doaj +1 more source
Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure
Arquivos Brasileiros de Cardiologia, 2015 Background: Matrix metalloproteinases (MMPs) are a family of enzymes important for the resorption of extracellular matrices, control of vascular remodeling and repair.
João Pedro Ferreira +5 more
doaj +1 more source